Search

Your search keyword '"Borghi, V"' showing total 533 results

Search Constraints

Start Over You searched for: Author "Borghi, V" Remove constraint Author: "Borghi, V"
533 results on '"Borghi, V"'

Search Results

3. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Borders and migrants in Europe

7. Missed treatment in an Italian HBV infected patients cohort: HBV RER

8. Research Handbook on Public Sociology

9. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

10. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

11. How to RESPOND to modern challenges for people living with HIV: A profile for a new cohort consortium

12. Efficacy and durability of two‐ vs . three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort

13. Hypokalemia in Patients with COVID-19

14. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

15. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

16. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14

18. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

20. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

21. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.

22. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen

23. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

26. Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors

27. Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

28. Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort

29. Re: 'No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir' by Calza et al

30. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors

31. Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study

32. Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience

33. Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort study

34. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

36. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

37. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

38. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

39. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients

40. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

46. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

48. Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.

Catalog

Books, media, physical & digital resources